Arkolith/Insider Trading/NKGN/Form 4

Graf James A

Interim CFO, 10% OwnerNKGen Biotech, Inc. (NKGN) · full profile →Form 4 · filed Oct 4, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 29, 2023Other(J)1.8M—$02.4M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 29, 2023Grant(A)4.7M$1.50$7.1M4.7M
Sep 29, 2023Grant(A)523K$1.50$785K5.2M

Transaction Codes

J
Other acquisition / disposition
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-23-106578) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML